TACSTD2 Recombinant Monoclonal Antibody

Code: CSB-RA023072MA5HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, WB, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P09758

Target Names

TACSTD2

Alternative Names

Cell surface glycoprotein Trop 2 antibody; Cell surface glycoprotein Trop-2 antibody; Cell surface glycoprotein Trop2 antibody; Epithelial glycoprotein 1 antibody; GA733 1 antibody; GA7331 antibody; M1S 1 antibody; M1S1 antibody; Membrane component chromosome 1 surface marker 1 antibody; Pancreatic carcinoma marker protein GA733 1 antibody; Pancreatic carcinoma marker protein GA733-1 antibody; Pancreatic carcinoma marker protein GA7331 antibody; TACD 2 antibody; TACD2_HUMAN antibody; TACSTD 2 antibody; Tacstd2 antibody; Trop 2 antibody; Trop2 antibody; Tumor associated calcium signal transducer 2 precursor antibody; Tumor-associated calcium signal transducer 2 antibody

Species Reactivity

Human

Immunogen

Recombinant Human TACSTD2 protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

mIgG2a

Clone No.

20D10

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol Western Blotting(WB) Protocol Flow Cytometry (FC) Protocol

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:2000
FC	1:50-1:200

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

Western Blot
Positive WB detected in: A-431 whole cell lysate(30µg)
All lanes: TACSTD2 antibody at 1:1000
Secondary
Goat polyclonal to mouse IgG at 1/40000 dilution
Predicted band size: 36 kDa
Observed band size: 36 kDa
Exposure time: 2min
Overlay Peak curve showing BxPC-3 cells stained with CSB-RA023072MA5HU (red line) at 1:100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated Goat Anti-Mouse IgG(H+L) at 1:200 dilution for 35min at 4℃.Control antibody (green line) was mouse IgG2a (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.

Description

TACSTD2, commonly known as Trop-2, is a transmembrane glycoprotein that has emerged as a compelling target in cancer research due to its overexpression across numerous epithelial carcinomas. This cell surface marker plays significant roles in calcium signal transduction and has been implicated in tumor cell proliferation, migration, and invasion, making it a valuable biomarker for studying oncogenic mechanisms and evaluating therapeutic strategies.

This recombinant monoclonal antibody, clone 20D10, offers the consistency and reliability that demanding research applications require. Produced using recombinant technology, it provides sequence-defined specificity and exceptional lot-to-lot reproducibility, ensuring your experimental results remain comparable across extended studies. The antibody was generated against recombinant human TACSTD2 protein, delivering precise target recognition for human samples.

Validation studies demonstrate robust performance across multiple platforms, giving you flexibility in your experimental workflow. Western blot analysis of A-431 whole cell lysate reveals a clean band at the predicted molecular weight of 36 kDa, confirming accurate target detection in this epidermoid carcinoma cell line at dilutions ranging from 1:500 to 1:2000. Flow cytometry validation using BxPC-3 pancreatic cancer cells shows clear positive staining with excellent separation from isotype control, supporting cell surface expression studies at dilutions of 1:50 to 1:200. The antibody is also validated for ELISA applications.

Supplied in a stabilized liquid format with glycerol for convenient long-term storage, this antibody is well-suited for researchers investigating TACSTD2 biology in cancer contexts, including studies of tumor progression, biomarker validation, and therapeutic target characterization.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

May function as a growth factor receptor.

Gene References into Functions

The results suggest that TROP2 expression could be an effective prognostic biomarker for oral squamous cell carcinoma PMID:30098828
TROP-2, SLP-2 and CD56 were effective diagnostic markers for PTC, especially when they were combined to use. PMID:29951933
Trop2 has a potential role in the promotion of EMT in BC. PMID:29901160
these results suggested that TROP2 may promote osteosarcoma cell proliferation and migration via PI3K/AKT signaling and may serve as a novel treatment target for osteosarcoma . PMID:29845216
TACSTD2 downregulation is associated with hepatocellular carcinoma. PMID:29538454
findings demonstrate that a membranous TROP-2 staining pattern is highly specific for PTC, which may serve as a potential diagnostic marker aiding in the accurate classification of morphologically equivocal thyroid follicular-patterned lesions PMID:26862947
TROP2 promoted the proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT. PMID:28423362
The results from clinical specimens showed that Trop2 expression correlated with MMP2 expression in primary thyroid cancer. The current study suggests that elevated expression of Trop2 may represent an important molecular hallmark that is biologically and clinically relevant to the progression of thyroid cancer. PMID:28709407
these results suggest a differential role for TROP2 in different lung cancer subtypes PMID:28404926
Results show that TROP2 expression is up-regulated in gastric tumor and its co-expression with AREG protein is associated with TNM stage, tumor size, lymph node metastases, and distant metastases. PMID:28256068
Our findings indicate that the expression of Trop-2 is a stringent predictor of tumor response to AKT inhibitors. They also support the identification of target-activatory pathways, as efficient predictors of response in precision cancer therapy. PMID:27022065
Findings suggest that high TROP2 expression identifies distinct cell sub-populations in androgen-sensitive and androgen-independent prostate tumors and that it may be a predictive biomarker for prostate cancer treatment response in androgen-sensitive tumors. PMID:27283984
TROP2 may play a crucial role in COPD by affecting basal cells function and thus airway remodeling through increased basal cells hyperplasia PMID:27887617
TROP2 was overexpressed specifically in the majority of epithelial ovarian cancer and may be a novel prognostic biomarker PMID:27127000
we compared the diagnostic value of TROP-2 expression in distinguishing between benign and malignant thyroid lesions to those of HBME-1, CK19 and galectin-3 PMID:28547974
TROP-2 membranous staining is a very sensitive and specific marker for the classic and tall cell variants of papillary thyroid carcinoma, and for papillary microcarcinomas , with high overall specificity for papillary thyroid carcinoma PMID:27311870
The results suggested that trop2 facilitated neovascularization of non-small-cell lung cancer via activating ERK1/2 signaling pathway. PMID:28345466
We identified a homozygous TACSTD2 missense mutation, c.551A>G, p.(Tyr184Cys), in the affected family members. Both parents were heterozygous for the mutation, and unaffected siblings were either heterozygous or homozygous wild-type for this allele. PMID:27227392
Our results expand the mutational spectrum of TACSTD2 in patients with gelatinous drop-like corneal dystrophy (GDLD). PMID:27149532
Trop2 expression was higher in GC tissues than in neighboring non-tumor tissues. Increased Trop2 protein levels in GC were associated with increased differentiation, tumor node metastasis stage, tumor size, lymph node metastasis, distant metastasis, and H. pylori infection. PMID:26716416
Trop-2 is a novel target for ADC therapy because of its high expression by many solid cancers. PMID:26101915
TROP2 is epigenetically down-regulated and operates as a negative regulator of cell proliferation and migration in liver fluke-associated cholangiocarcinoma. PMID:26626643
TROP-2 is specifically expressed in papillary thyroid carcinoma. PMID:26481593
overexpression of TROP2 appears to be an independent predictor for poor clinical outcome in nasopharyngeal carcinoma PMID:26617817
Lower GA733-2 expression in cancer tissues appeared to correlate with lymph node metastases (P < 0.05). GA733-1 gene expression was significantly higher in cancerous samples PMID:26600538
TROP-2 can be used as well as HBME-1 in thyroid cytology to detect PTC. PMID:25164548
Altogether, our data suggest that TROP2 plays an important role in promoting ADC and may represent a novel prognostic biomarker and therapeutic target for the disease. PMID:26773504
TROP2 protein is expressed at high levels in the colon cancer tissues. PMID:26059528
TACSTD2 protein, human is predicting lymph node metastases in OSCC, overall survival and disease-free survival. PMID:24764155
The amino acid exchange resulting from 4461T[C does not appear to alter binding of HO-3, suggesting that treatment with catumaxomab can be offered to patients regardless of their TACSTD1-genotype. PMID:26115884
These observations suggest that Trop2 serves an oncogenic role in LSCC and has potential as a therapeutic target PMID:25779928
This study reveals that both EpCAM and Trop2 overexpression in pituitary adenomas correlate significantly with invasiveness and proliferation. Follow-up analysis shows that Trop2 is a predictive factor for recurrence/progression for PAs. PMID:25550831
Trop2 loss triggers sensitivity to anti-ErbB3 antibodies, which results in reduced proliferation and tumorigenic growth of Trop2 negative head and neck squamous cell cancer cells. PMID:25238142
studies have begun to identify the mechanisms underlying TROP2's functions, including regulated intramembrane proteolysis or specific interactions with integrin b1 and claudin proteins. PMID:25523132
we demonstrate that the Trop-2 activation states are critical determinants of tumor progression and are powerful indicators of breast cancer patients survival. PMID:24824621
Inhibition of Tacstd2 expression significantly inhibited chemotherapeutic reagent-induced apoptosis, and TACSTD2 regulated apoptotic gene expression through P63 containing the transactivation domain (TAp63). PMID:24651436
Trop2 is important in proliferation and apoptosis regulation in CaSki cells, which may become a novel target for cervical cancer treatment. PMID:24816726
Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PMID:24086649
miR-125b-1 causes mitogen-activated protein kinase pathway dysfunction through regulation of TACSTD2 expression. PMID:23416980
The results of this study suggested that the TROP2 correlated with malignancy, proliferation and angiogenesis in human gliomas PMID:23397225
TROP2 gene expression can be used as an independent prognostic indicator for squamous cell carcinoma of the larynx. PMID:22987366
Used the Sf9 cells to express the Trop2 ectodomain (Trop2EC) in two forms - wt glycosylated (gTrop2EC) and mutant non-glycosylated form (Trop2EC(Delta/N)). Recombinant protein was purified and structure studied. PMID:23872121
Trop2 expression reflects a more malignant phenotype and may serve as an unfavorable prognostic factor for extranodal NK/T cell lymphoma, nasal type PMID:23979406
The cells exhibited a low epithelial barrier function as well as decreased expression of tight-junction-related proteins claudin 1 and 7. PMID:23868985
show that Trop-2 enhances directional prostate cancer cell migration, through modulation of Rac1 GTPase activity PMID:23536555
Network hubs and interacting partners are co-expressed with Trop-2 in primary human tumours, supporting a role of this signalling network in cancer growth. PMID:22562244
study characterized the expression of TACSTD2 in invasive ductal breast cancer(IDC) and adjacent non-malignant tissues; studies demonstrated that the high expression of TACSTD2 correlates with a poor prognosis in IDC PMID:23031786
Our data support a model where above-baseline expression of wild-type Trop-2 is a key driver of human cancer growth. PMID:22349828
High expression of TROP2 was associated with stage stage IIb colon cancer. PMID:23055188
More than 90% of Gelatinous drop-like corneal dystrophy (GDLD) patients possessed the same haplotype with a Q118X mutation in TACSTD2. PMID:23038033